Therapeutic effects of Qiliqiangxin capsule on heart failure in aging rats after acute myocardial infarction
Objective To investigate the impact of QiliQiangXin Capsules on ventricular remodeling and cardiac contraction and relaxation function in aging rats with heart failure following myocardial infarction.Methods From August 2022 to August 2023,a total of 30 old rats were randomly assigned to three groups:sham-operated group,model group,and treatment group,with 10 rats in each group selected through a digital lottery method.The model and treatment groups were created by ligating the anterior descending branch of the left coronary artery.The rats in the treatment group received daily administration of Astragalosa hebecarpa Drabanemerosa Strong Heart Capsule(1.0 g/kg)via gavage after 4 weeks.After the 4-week drug administration period,echocardiography was performed to measure various parameters including left ventricular end-diastolic internal diameter(LVIDd),left ventricular end-systolic internal diameter(LVIDs),left ventricular ejection fraction(LVEF),left ventricular anterior wall myocardial thickness(LVAWd),mitral valve early diastolic peak flow velocity(E peak),and early diastolic velocity of mitral annulus(e peak)detected by tissue Doppler(TDI).The E/e value was calculated based on these measurements.Additionally,serum levels of B-type brain natriuretic peptide(BNP),matrix metalloproteinase 2(MMP-2),matrix metalloproteinase 9(MMP-9),and tumor necrosis factor(TNF-a)were measured using enzyme-linked immunosorbent assay(ELISA).Hematoxylin-eosin(HE)staining was employed to observe the morphological changes in myocardial tissue.Results Compared to rats in the model group,rats in the treatment group exhibited lower left ventricular internal dimension at end-diastole(LVIDd)(9.1±0.6 mm vs.11.4± 0.8 mm,P＜0.01),lower left ventricular internal dimension at end-systole(LVIDs)(5.9±0.8 mm vs.8.7±0.9 mm,P＜0.01),lower E/e ratio(13.4±2.0 vs.16.3±2.8,P＜0.05),higher left ventricular ejection fraction(LVEF)(68.8±7.1％vs.52.0±8.4％,P＜0.01),and elevated left ventricular anterior wall thickness at end-diastole(LVAWd)(1.5±0.2 mm vs.1.2±0.3 mm,P＜0.05).In addition,compared to rats in the model group,the treatment group showed a decrease in brain natriuretic peptide(BNP)(0.26±0.04 μg/L vs.0.34±0.05 μg/L,P＜0.01),decreased matrix metalloproteinase-2(MMP-2)(3697.0±857.7 μg/L vs.4719.5±703.5 μg/L,P＜0.01),decreased matrix metalloproteinase-9(MMP-9)(87.3±13.8 μg/L vs.116.5±9.6 μg/L,P＜0.01),decreased tumor necrosis factor-alpha(TNF-α)(165.3±36.9 μg/L vs.269.8±35.0 μg/L,P＜0.01),and lower TNF-α levels(165.3±36.9 μg/L vs.269.8±35.0 μg/L,P＜0.01).Histological examination using hematoxylin and eosin(HE)staining revealed that the treatment group had less severe cardiac myocyte arrangement disorder and inflammatory reaction compared to the model group.Conclusions Qiliqiangxin Capsules were found to effectively delay ventricular remodeling and improve myocardial contraction and relaxation function in aging rats with heart failure after acute myocardial infarction.
NETL
NSTL
万方数据
维普
